跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Retavacyl 250 - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Retavacyl 250
Approved
STANDARD
Retavacyl 250
Yeluri Formulations Pvt. Ltd
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
0441f915a7f97785
Company
Yeluri Formulations Pvt. Ltd
Type
Standard
Approval Details
Approval Id
0441f915a7f97785
Drug Approval Philippines Name
Retavacyl 250
Product Name
Retavacyl 250
Registration Number
DRP-12921-05
Brand Name
Retavacyl 250
Generic Name
Co-Amoxiclav
Dosage Form
Powder for Oral Suspension
Dosage Strength
312.5 mg/5 mL
Manufacturer
Yeluri Formulations Pvt. Ltd
Importer
Medinova Pharmaceutical Inc
Distributor
Reta Drug
Issuance Date
25 July 2024
Expiry Date
28 October 2027
Pharmacologic Category
Antibacterial (Penicillin + Beta-Lactamase Inhibitor)
Classification
Prescription Drug (Rx)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
0441f915a7f97785
Type
Standard
Back to Philippines FDA Approvals